Kazia Therapeutics (NASDAQ:KZIA) Coverage Initiated at Maxim Group

Maxim Group began coverage on shares of Kazia Therapeutics (NASDAQ:KZIA) in a research note released on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $3.00 price target on the stock.

Kazia Therapeutics Trading Up 7.1 %

KZIA opened at $1.50 on Thursday. The business’s 50-day simple moving average is $2.48 and its 200-day simple moving average is $3.73. Kazia Therapeutics has a one year low of $1.31 and a one year high of $15.80.

Institutional Trading of Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management purchased a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned approximately 51.66% of Kazia Therapeutics at the end of the most recent reporting period. 30.89% of the stock is owned by institutional investors and hedge funds.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.